local_hospital

Hillerod Hospital

Address
Dyrehavevej 29, 3400 Hillerød, Denmark

Infectious Diseases

The department focuses on viral and bacterial infections, aiming to improve treatment options and patient outcomes across a range of serious illnesses.

  • HSV-2 meningitis – evaluating antiviral therapy effectiveness.
  • COVID-19 in high‑risk non‑hospitalized adults – testing oral antivirals.
  • Staphylococcus aureus bacteremia – comparing short versus extended antibiotic courses.
  • Sepsis and septic shock – assessing empirical antibiotic strategies in intensive care.
  • Chronic rhinosinusitis without nasal polyps – investigating novel anti‑inflammatory agents.

These studies seek to refine diagnostics, reduce mortality, and enhance quality of care for patients facing infectious threats.

Oncology

Research in the oncology field targets breast cancer subtypes, exploring new targeted therapies and combination regimens to extend survival.

  • HR+/HER2‑ advanced/metastatic breast cancer – testing kinase inhibitors with endocrine therapy.
  • HER2‑positive metastatic breast cancer – evaluating antibody‑drug conjugates, with and without brain metastases.
  • Node‑positive estrogen receptor‑positive early breast cancer – assessing novel endocrine agents for recurrence prevention.

The goal is to demonstrate superior disease control and improve long‑term outcomes for women and men affected by breast cancer.

Gastroenterology

The site conducts trials in inflammatory bowel disease, focusing on both ulcerative colitis and Crohn’s disease to find safer, more effective treatments.

  • Moderately to severely active Crohn's disease – oral selective inhibitors evaluated for remission.
  • Moderately to severely active ulcerative colitis – endoscopic response and clinical remission as primary endpoints.

Long‑term safety and tolerability are also examined to support sustained disease management.

Cardiology

Cardiovascular research addresses chronic heart failure, seeking interventions that lower mortality and reduce hospital admissions.

  • Chronic heart failure with reduced ejection fraction – testing hydralazine‑ISDN and metformin as adjunct therapies.

By targeting neuro‑hormonal pathways and metabolic modulation, these trials aim to improve functional capacity and survival.

Orthopedics

Orthopedic investigations evaluate pain management and functional recovery for common fracture injuries.

  • Distal radius fracture – ultrasound‑guided brachial plexus nerve block compared with standard care.

The study measures analgesic effectiveness and facilitates early mobilization after closed reduction.

Critical Care

The intensive care platform explores best practices for patients admitted with life‑threatening conditions, aiming to standardize care across clinicians.

  • Acute critical illness requiring ICU admission – platform trial assessing varied interventions.
  • Sepsis and septic shock – evaluating mortality and organ support outcomes.

Findings are intended to inform evidence‑based protocols and improve survival rates in the ICU setting.

Site Overview

assignment
50
connected trials
corporate_fare
26
sponsors
science
192
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
50
Total trials linked
Highly Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 17 therapeutic areas and 15 of 192 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 167 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
30
Sponsors (total)
26
Active sponsors
16

Sponsor Network

Top 16 by active trials.

lock +15 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +8 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
50
Outperforms 87% of sites
public
Therapeutic diversity
17areas
Outperforms 89% of sites
groups
Sponsor diversity
26sponsors
Outperforms 86% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Hillerod Hospital

lock Showing 1 of 50 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh StudyInsmed Inc.Phase IINot RecruitingMay 2024Oct 2025

IMP list

lock Showing 1 of 192 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Semaglutide4Unknown2023-01-122025-05-15

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.